Expression of hepatitis B virus surface antigen determinants in Lactococcus lactis for oral vaccination

Microbiological Research

Volumn 166, Issue 2, 2011, Pages 111-120

  Zhang, Qiuxiang ^a,b   Zhong, Jin ^a   Huan, Liandong ^a  

^a INSTITUTE OF MICROBIOLOGY   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

Author keywords

Adjuvant; HBV; Interferon; Lactococcus lactis; Oral immunization

Indexed keywords

ADJUVANT; ANTIBODY RESPONSE; BALB/C MICE; BIOLOGICALLY ACTIVE PROTEINS; FOOD GRADE; FUSION PROTEINS; HBV; HEPATITIS B VIRUS; IMMUNE RESPONSE; LACTOCOCCUS LACTIS; MUCOSAL VACCINE; NISIN-CONTROLLED; ORAL IMMUNIZATION; PRE-S REGION; SURFACE ANTIGEN; WESTERN-BLOT ANALYSIS;

ANTIGENS; GLYCOPROTEINS; IMMUNIZATION; VACCINES; VIRUSES;

ANTIBIOTICS;

ALPHA2B INTERFERON; HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOLOGICAL ADJUVANT; PRESURFACE PROTEIN 2, HEPATITIS B SURFACE ANTIGEN; PROTEIN PRECURSOR; RECOMBINANT VACCINE;

ANTIGEN; BACTERIUM; HEPATITIS; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOASSAY; PROTEIN; VACCINATION; VIRAL DISEASE;

ANIMAL; ARTICLE; BAGG ALBINO MOUSE; BLOOD; ESCHERICHIA COLI; FEMALE; GENETICS; HUMAN; IMMUNOLOGY; LACTOCOCCUS LACTIS; MOUSE; ORAL DRUG ADMINISTRATION; RANDOMIZATION; SECRETION;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, ORAL; ANIMALS; ESCHERICHIA COLI; FEMALE; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INTERFERON ALFA-2B; LACTOCOCCUS LACTIS; MICE; MICE, INBRED BALB C; PROTEIN PRECURSORS; RANDOM ALLOCATION; VACCINES, SYNTHETIC;

BACTERIA (MICROORGANISMS); HEPATITIS B VIRUS; LACTOCOCCUS; LACTOCOCCUS LACTIS; MUS;

EID: 78651416505     PISSN: 09445013     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.micres.2010.02.002     Document Type: Article

References (35)

1. Bermudez-Humaran LG, Cortes-Perez NG, Le Loir Y, Alcocer-Gonzalez JM, Tamez-Guerra RS, de Oca-Luna RM, et al. An inducible surface presentation system improves cellular immunity against human papillomavirus type 16 E7 antigen in mice after nasal administration with recombinant lactococci. J Med Microbiol 2004, 53(Pt 5):427-433.
2. Bracci L, La Sorsa V, Belardelli F, Proietti E Type I interferons as vaccine adjuvants against infectious diseases and cancer. Expert Rev Vaccines 2008, 7(3):373-381.
3. Bracci L, Canini I, Puzelli S, Sestili P, Venditti M, Spada M, et al. Type I IFN is a powerful mucosal adjuvant for a selective intranasal vaccination against influenza virus in mice and affects antigen capture at mucosal level. Vaccine 2005, 23(23):2994-3004.
4. Chen H Recent advances in mucosal vaccine development. J Control Release 2000, 67(2-3):117-128.
5. Gasson MJ. Plasmid complements of Streptococcus lactis NCDO 712 and other lactic streptococci after protoplast-induced curing. J Bacteriol 1983, 154(1):1-9.
6. Heermann KH, Goldmann U, Schwartz W, Seyffarth T, Baumgarten H, Gerlich WH Large surface proteins of hepatitis B virus containing the preS sequence. J Virol 1984, 52(2):396-402.
7. Holo H, Nes IF High-frequency transformation, by electroporation, of Lactococcus lactis subsp. cremoris grown with glycine in osmotically stabilized media. Appl Environ Microbiol 1989, 55(12):3119-3123.
8. Hou XL, Yu LY, Liu J, Wang GH Surface-displayed porcine epidemic diarrhea viral (PEDV) antigens on lactic acid bacteria. Vaccine 2007, 26(1):24-31.
9. Itoh Y, Takai E, Ohnuma H, Kitajima K, Tsuda F, Machida A, et al. A synthetic peptide vaccine involving the product of the pre-S(2) region of hepatitis B virus DNA: protective efficacy in chimpanzees. Proc Natl Acad Sci USA 1986, 83(23):9174-9178.
10. Kuipers OP., de Ruyter PGGA., Kleerebezem M., de Vos WM. Quorum sensing-controlled gene expression in lactic acid bacteria. J Biotechnol 1998, 64:15-21.
11. Kumar GB, Ganapathi TR, Bapat VA Production of hepatitis B surface antigen in recombinant plant systems: an update. Biotechnol Prog 2007, 23(3):532-539.
12. Le Loir Y, Gruss A, Ehrlich SD, Langella P A nine-residue synthetic propeptide enhances secretion efficiency of heterologous proteins in Lactococcus lactis. J Bacteriol 1998, 180(7):1895-1903.
13. Le Loir Y, Azevedo V, Oliveira SC, Freitas DA, Miyoshi A, Bermudez-Humaran LG, et al. Protein secretion in Lactococcus lactis: an efficient way to increase the overall heterologous protein production. Microb Cell Fact 2005, 4(1):2.
14. Mason HS, Lam DM, Arntzen CJ Expression of hepatitis B surface antigen in transgenic plants. Proc Natl Acad Sci USA 1992, 89(24):11745-11749.
15. McGhee JR, Mestecky J In defense of mucosal surfaces. Development of novel vaccines for IgA responses protective at the portals of entry of microbial pathogens. Infect Dis Clin North Am 1990, 4(2):315-341.
16. Mishiro S, Imai M, Takahashi K, Machida A, Gotanda T, Miyakawa Y, et al. A 49,000-dalton polypeptide bearing all antigenic determinants and full immunogenicity of 22-nm hepatitis B surface antigen particles. J Immunol 1980, 124(4):1589-1593.
17. Neurath AR, Seto B, Strick N Antibodies to synthetic peptides from the preS1 region of the hepatitis B virus (HBV) envelope (env) protein are virus-neutralizing and protective. Vaccine 1989, 7(3):234-236.
18. Norton PM, Wells JM, Brown HW, Macpherson AM, Le Page RW Protection against tetanus toxin in mice nasally immunized with recombinant Lactococcus lactis expressing tetanus toxin fragment C. Vaccine 1997, 15(6-7):616-619.
19. Nouaille S, Ribeiro LA, Miyoshi A, Pontes D, Le Loir Y, Oliveira SC, et al. Heterologous protein production and delivery systems for Lactococcus lactis. Genet Mol Res 2003, 2(1):102-111.
20. Pei H, Liu J, Cheng Y, Sun C, Wang C, Lu Y, et al. Expression of SARS-coronavirus nucleocapsid protein in Escherichia coli and Lactococcus lactis for serodiagnosis and mucosal vaccination. Appl Microbiol Biotechnol 2005, 68(2):220-227.
21. Proietti E, Bracci L, Puzelli S, Di Pucchio T, Sestili P, De Vincenzi E, et al. Type I IFN as a natural adjuvant for a protective immune response: lessons from the influenza vaccine model. J Immunol 2002, 169(1):375-383.
22. Rendi-Wagner P, Shouval D, Genton B, Lurie Y, Rumke H, Boland G, et al. Comparative immunogenicity of a PreS/S hepatitis B vaccine in non- and low responders to conventional vaccine. Vaccine 2006, 24(15):2781-2789.
23. Richter LJ, Thanavala Y, Arntzen CJ, Mason HS Production of hepatitis B surface antigen in transgenic plants for oral immunization. Nat Biotechnol 2000, 18(11):1167-1171.
24. Robinson K, Chamberlain LM, Schofield KM, Wells JM, Le Page RW Oral vaccination of mice against tetanus with recombinant Lactococcus lactis. Nat Biotechnol 1997, 15(7):653-657.
25. Scavone P, Miyoshi A, Rial A, Chabalgoity A, Langella P, Azevedo V, et al. Intranasal immunisation with recombinant Lactococcus lactis displaying either anchored or secreted forms of Proteus mirabilis MrpA fimbrial protein confers specific immune response and induces a significant reduction of kidney bacterial colonisation in mice. Microbes Infect 2007, 9(7):821-828.
26. Schreuder MP, Deen C, Boersma WJ, Pouwels PH, Klis FM Yeast expressing hepatitis B virus surface antigen determinants on its surface: implications for a possible oral vaccine. Vaccine 1996, 14(5):383-388.
27. Sheu SY, Lo SJ Deletion or alteration of hydrophobic amino acids at the first and the third transmembrane domains of hepatitis B surface antigen enhances its production in Escherichia coli. Gene 1995, 160(2):179-184.
28. Shouval D, Ilan Y, Adler R, Deepen R, Panet A, Even-Chen Z, et al. Improved immunogenicity in mice of a mammalian cell-derived recombinant hepatitis B vaccine containing pre-S1 and pre-S2 antigens as compared with conventional yeast-derived vaccines. Vaccine 1994, 12(15):1453-1459.
29. Singh M, O'Hagan D Advances in vaccine adjuvants. Nat Biotechnol 1999, 17(11):1075-1081.
30. Tiollais P, Pourcel C, Dejean A The hepatitis B virus. Nature 1985, 317(6037):489-495.
31. Valenzuela P, Medina A, Rutter WJ, Ammerer G, Hall BD Synthesis and assembly of hepatitis B virus surface antigen particles in yeast. Nature 1982, 298(5872):347-350.
32. Waters JA, Brown SE, Steward MW, Howard CR, Thomas HC Analysis of the antigenic epitopes of the Hepatitis B surface antigen involved in the induction of a protective antibody response. Virus Res 1991, 22:1-12.
33. Wells JM, Wilson PW, Norton PM, Gasson MJ, Le Page RW Lactococcus lactis: high-level expression of tetanus toxin fragment C and protection against lethal challenge. Mol Microbiol 1993, 8(6):1155-1162.
34. Wells JM, Robinson K, Chamberlain LM, Schofield KM, Le Page RW Lactic acid bacteria as vaccine delivery vehicles. Antonie Van Leeuwenhoek 1996, 70(2-4):317-330.
35. Xin KQ, Hoshino Y, Toda Y, Igimi S, Kojima Y, Jounai N, et al. Immunogenicity and protective efficacy of orally administered recombinant Lactococcus lactis expressing surface-bound HIV Env. Blood 2003, 102(1):223-228.